How Compounded Semaglutide and Tirzepatide Access Works Through a Virtual GLP-1 Program With No Insurance Required in 2026Wilmington, DE, May 01, 2026 (GLOBE NEWSWIRE) -- Compounded semaglutide and ...

Americans' voracious appetite for GLP-1 weight loss drugs has the nation on pace to spend more than $1 trillion on ...

The program integrates primary care, pharmacy and virtual services to provide coordinated, longitudinal obesity treatment.

Massachusetts and Rhode Island are considering dropping GLP-1 drugs for obesity treatment from their Medicaid programs, ...

The weight loss drug market may reach almost $100 billion in a few years.

Big news for seniors: A new Medicare program will cover popular GLP-1 weight-loss drugs like Wegovy starting July 2026. Learn ...

While GLP-1 medications first gained visibility for diabetes care and later for weight loss, researchers are now evaluating ...

A Senate-passed proposal to restore access to GLP-1 medications for weight loss for adults on the Medicaid program got a big ...

Amgen has launched a late-stage program to test the feasibility of switching patients from weekly GLP-1 injections to its own ...

Company announcement - No. 10 / 2026 Zealand Pharma announces Boehringer Ingelheim's novel glucagon/GLP-1 dual agonist survodutide achieved significant weight loss of 16.6% delivering meaningful metab ...

In SYNCHRONIZE-1, participants lost up to an average of 39.2 lb (17.8 kg) from baseline after 76 weeks of treatment with survodutide, a glucagon/GLP-1 receptor dual agonist1The trial met both weight l ...